{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:07:33Z","timestamp":1790197653051,"version":"4.1.0"},"reference-count":43,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CCID"],"DOI":"10.2147\/ccid.s381471","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T02:05:15Z","timestamp":1691546715000},"page":"2135-2142","source":"Crossref","is-referenced-by-count":28,"title":["Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Layna","family":"Mager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Gardeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn T","family":"Shahwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.ejca.2015.06.110","volume":"51","author":"Stratigos","year":"2015","journal-title":"Eur J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S1470-2045(08)70178-5","volume":"9","author":"Brantsch","year":"2008","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamadermatol.2015.4994","volume":"152","author":"Thompson","year":"2016","journal-title":"JAMA Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaad.2022.06.1169","volume":"88","author":"Soleymani","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref5","unstructured":"European Medicines Agency. Libtayo (cemiplimab): EU public assessment report [homepage on the internet]; 2019. Available from: http:\/\/www.ema.europa.eu. Accessed March 16, 2023."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.007","volume":"128","author":"Stratigos","year":"2020","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.3390\/ijms21082956","volume":"21","author":"Corchado-Cobos","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref9","unstructured":"Regeneron Pharmaceuticals Inc. Libtayo (cemiplimab): US prescribing information [homepage on the internet]; 2019. Available from: http:\/\/www.regeneron.com. Accessed March 13, 2023."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"ref11","unstructured":"NCI Dictionaries [homepage on the internet]. USA: RECIST; 2023. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/recist. Accessed March 16, 2023."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e002757","DOI":"10.1136\/jitc-2021-002757","volume":"9","author":"Rischin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e000775","DOI":"10.1136\/jitc-2020-000775","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2021.02.041","volume":"149","author":"Pham","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e590","DOI":"10.1111\/jdv.18082","volume":"36","author":"Challapalli","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/bjd.20569","volume":"185","author":"Guillaume","year":"2021","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.3390\/cancers13143547","volume":"13","author":"Hober","year":"2021","journal-title":"Cancers"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"T610","DOI":"10.1016\/j.ad.2022.05.001","volume":"113","author":"R\u00edos-Vi\u00f1uela","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"686308","DOI":"10.3389\/fonc.2021.686308","volume":"11","author":"Strippoli","year":"2021","journal-title":"Front Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jgo.2021.02.026","volume":"12","author":"Valentin","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2217\/imt-2021-0191","volume":"14","author":"Swanson","year":"2022","journal-title":"Immunotherapy"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3390\/cancers15020495","volume":"15","author":"Bailly-Caill\u00e9","year":"2023","journal-title":"Cancers"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/IOP.0000000000002190","volume":"38","author":"Steren","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"796197","DOI":"10.3389\/fonc.2021.796197","volume":"11","author":"McLean","year":"2022","journal-title":"Front Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/bjophthalmol-2021-319417","volume":"107","author":"Goldfarb","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/lary.29953","volume":"132","author":"Wu","year":"2022","journal-title":"Laryngoscope"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/onco.13539","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1758835920977002","DOI":"10.1177\/1758835920977002","volume":"12","author":"Saponara","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/cbr.2021.0368","volume":"37","author":"Filippi","year":"2022","journal-title":"Cancer Biother Radiopharm"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40644-021-00426-2","volume":"21","author":"McLean","year":"2021","journal-title":"Cancer Imaging"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamadermatol.2016.4920","volume":"153","author":"Garrett","year":"2017","journal-title":"JAMA Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/hed.26546","volume":"43","author":"Ritter","year":"2021","journal-title":"Head Neck"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","volume":"20","author":"Portuguese","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2217\/fon-2019-0762","volume":"16","author":"Migden","year":"2020","journal-title":"Future Oncol"},{"key":"ref39","unstructured":"Study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03969004. Accessed April, 2023."},{"key":"ref40","unstructured":"Neoadjuvant cemiplimab for the treatment of resectable NSCLC, HCC, and HNSCC. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03916627. Accessed April, 2023."},{"key":"ref41","unstructured":"A PD-1 checkpoint inhibitor (Cemiplimab) for high-risk localized, locally recurrent, or regionally advanced skin cancer. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315701. Accessed April, 2023."},{"key":"ref42","unstructured":"Cemiplimab before and after surgery for the treatment of high risk cutaneous squamous cell cancer. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT4428671. Accessed April, 2023."},{"key":"ref43","unstructured":"Cemiplimab in AlloSCT\/SOT recipients with CSCC (CONTRAC). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04339062. Accessed March\u2013April, 2023."}],"container-title":["Clinical, Cosmetic and Investigational Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=91861","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=91861","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T02:05:22Z","timestamp":1691546722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/cemiplimab-for-the-treatment-of-advanced-cutaneous-squamous-cell-carci-peer-reviewed-fulltext-article-CCID"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":43,"URL":"https:\/\/doi.org\/10.2147\/ccid.s381471","relation":{},"ISSN":["1178-7015"],"issn-type":[{"value":"1178-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}